Clinical Trial Detail

NCT ID NCT01107522
Title Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Recruitment Unknown status
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tactical Therapeutics, Inc.
Indications

glioblastoma multiforme

Advanced Solid Tumor

malignant glioma

Therapies

Carboxyamidotriazole Orotate + Temozolomide

Carboxyamidotriazole Orotate

Age Groups: adult

No variant requirements are available.